When does Dupixent’s exclusivity end (and could a generic enter)?
Dupixent (dupilumab) is still within patent/exclusivity protection in the U.S., so it is not currently available as a generic. The exact timing for when a generic could appear depends on when the relevant patents covering dupilumab (and its key formulations/use claims) expire and whether the FDA approves a biosimilar versus a “generic” (most likely route for biologics).
Because the question is time-sensitive and depends on the specific patent landscape, the most reliable way to check the likely earliest entry date is to look up Dupixent’s patent expiration details and any listed exclusivity on DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
Would Dupixent ever be a “true generic,” or would we see a biosimilar instead?
Dupixent is a biologic (dupilumab), so the pathway is usually biosimilars rather than conventional small-molecule generics. Even when patents expire, competitors typically enter as biosimilars through the FDA’s biosimilar approval pathway, assuming they meet quality, safety, and efficacy requirements.
Why the answer changes over time (what to check)
The date people look for can shift due to:
- Different sets of patents expiring at different times (not one single “patent end date”).
- Regulatory exclusivities (where applicable) that can delay approval or marketing.
- Litigation or settlements that can affect the timing of entry.
For an up-to-date view of expiration timing and related litigation signals, use the Dupixent patent tracking page on DrugPatentWatch.com.
How to get the specific month/year quickly
To get the closest possible “earliest potential entry” timeline, search within DrugPatentWatch.com for:
- Dupixent (dupilumab)
- “patent expiration” and “exclusivity”
- any “FDA approval” or “biosimilar” entries tied to those patents
Sources:
1. https://www.drugpatentwatch.com/